Testing strong line metallicity diagnostics at z~2

High-z galaxy gas-phase metallicities are usually determined through observations of strong optical emission lines with calibrations tied to the local universe. Recent debate has questioned if these calibrations are valid in the high-z universe. We investigate this by analysing a sample of 16 galaxies at z~2 available in the literature, and for which the metallicity can be robustly determined using oxygen auroral lines. The sample spans a redshift range of 1.4 < z < 3.6, has metallicities of 7.4-8.4 in 12+log(O/H) and stellar masses 10^7.5-10^11 Msun. We test commonly used strong line diagnostics (R23, O3, O2, O32, N2, O3N2 and Ne3O2 ) as prescribed by four different sets of empirical calibrations, as well as one fully theoretical calibration. We find that none of the strong line diagnostics (or calibration set) tested perform consistently better than the others. Amongst the line ratios tested, R23 and O3 deliver the best results, with accuracies as good as 0.01-0.04 dex and dispersions of ~0.2 dex in two of the calibrations tested. Generally, line ratios involving nitrogen predict higher values of metallicity, while results with O32 and Ne3O2 show large dispersions. The theoretical calibration yields an accuracy of 0.06 dex, comparable to the best strong line methods. We conclude that, within the metallicity range tested in this work, the locally calibrated diagnostics can still be reliably applied at z~2.Comment: 12 pages, 8 Figures, accepted for publication in MNRA

Control of Ralstonia solanacearum in tomato potting medium by the use of a solar collector.

A solar collector was used to disinfest potting medium inoculated with Ralstonia solanacearum. Tomato plantlets grown in the potting medium treated in the solar collector for one full day had no symptoms of bacterial wilt

The group inverse of the nivellateur

We shall derive necessary and sufficient conditions for the nivellateur to have a group inverse over an algebraically closed field. We then extend these results to arbitrary fields.- Partially supported by FCT-'Fundacao para a Ciencia e a Tecnologia', within the project [UID-MAT-00013/2013]

Impact of Obesity on Results after Primary Angioplasty in Patients with ST Segment Elevation Acute Myocardial Infarction

INTRODUCTION: Obesity is an important risk factor for the development of diabetes, hypertension, coronary disease, left ventricular dysfunction, stroke and cardiac arrhythmias. Paradoxically, previous studies in patients undergoing elective coronary angioplasty showed a reduction in hospital and long-term mortality in obese patients. The relation with body mass index (BMI) has been less studied in the context of primary angioplasty. OBJECTIVES: To evaluate the impact of obesity on the results of ST-segment elevation acute myocardial infarction treated by primary angioplasty. METHODS: This was a study of 464 consecutive patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty, 78% male, mean age 61 +/- 13 years. We assessed in-hospital, 30-day and one-year mortality according to BMI. Patients were divided into three groups according to BMI: normal--18-24.9 kg/m2 (n = 171); overweight--25-29.9 kg/m2 (n = 204); and obese-- > 30 kg/m2 (n = 89). RESULTS: Obese patients were younger (ANOVA, p < 0.001) and more frequently male (p = 0.014), with more hypertension (p = 0.001) and dyslipidemia (p = 0.006). There were no differences in the prevalence of diabetes, previous cardiac history, heart failure on admission, anterior location, multivessel disease, peak total CK or medication prescribed, except that obese patients received more beta-blockers (p = 0.049). In-hospital mortality was 9.9% for patients with normal BMI, 3.4% for overweight patients and 6.7% for obese patients (p = 0.038). Mortality at 30 days was 11 4.4% and 7.8% (p = 0.032) and at one year 12.9%, 4.9% and 9% (p = 0.023), respectively. On univariate analysis, overweight was the only BMI category with a protective effect; however, after multivariate logistic regression analysis, adjusted for confounding variables, none of the BMI categories could independently predict outcome. CONCLUSIONS: Overweight patients had a better prognosis after primary angioplasty for ST-segment elevation acute myocardial infarction compared with other BMI categories, but this was dependent on other potentially confounding variables

Very Late Coronary Stent Thrombosis After Discontinuation of Antiplatelet Therapy

Percutaneous transluminal coronary angioplasty (PTCA) with stent placement is widely used to achieve myocardial revascularization in patients with symptomatic ischemic heart disease and significant coronary artery stenosis. Drug-eluting stents are used in most patients undergoing percutaneous angioplasty. Stent thrombosis is an uncommon but serious complication, manifested mostly by sudden death or acute ST-elevation myocardial infarction. The authors report the case of a 68-year-old patient with acute anterior ST-elevation myocardial infarction. Five years previously, she had had a similar presentation and underwent primary angioplasty of the left anterior descending artery with implantation of a drug-eluting stent. The patient was discharged under antithrombotic therapy. She discontinued antiplatelet therapy and two days later suffered an acute anterior myocardial infarction. Primary angioplasty revealed stent thrombosis

Benefits measurement of a plan to reduce hypertension in a healthcare foundation using the BCTool

The hypertension is a well know problem and associated with a high salt consuming is one of the commonest chronic diseases.To measure the impact of this consuming it has been applied the methodology provided by the Business Case tool (BC Tool), in a Portuguese foundation for elderly, in order to contribute for Intervention Plan for the reduction of hypertension which aims to reduce salt consumption in the Portuguese population and to improve the control of Hypertension through a phased reduction in salt consumption.This objective has been achieved by changing the availability of foods with lower salt contents and by decreasing the addition of salt in cooking. The results of these measures provided a substantial benefit in terms of Benefits Measurements and Cost Analysis besides the results of SROI measurement in order to obtain the social benefits of this initiative of the Intervention plan to reduce hypertension. Along these results it has been collected the suggestions for improvements that would allow the Sarah Beirão Foundation's response to the needs of its users to be improved.info:eu-repo/semantics/publishedVersio

Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver

<p>Abstract</p> <p>Background</p> <p>CETP is a plasma protein that modulates atherosclerosis risk through its HDL-cholesterol reducing action. The aim of this work was to examine the effect of the PPARα agonist, ciprofibrate, on the CETP gene expression, in the presence and absence of apolipoprotein (apo) CIII induced hypertriglyceridemia, and its impact on the HDL metabolism.</p> <p>Results</p> <p>Mice expressing apo CIII and/or CETP and non-transgenic littermates (CIII, CIII/CETP, CETP, non-Tg) were treated with ciprofibrate during 3 weeks. Drug treatment reduced plasma triglycerides (30-43%) and non-esterified fatty acids (19-47%) levels. Cholesterol (chol) distribution in plasma lipoprotein responses to ciprofibrate treatment was dependent on the genotypes. Treated CIII expressing mice presented elevation in VLDL-chol and reduction in HDL-chol. Treated CETP expressing mice responded with reduction in LDL-chol whereas in non-Tg mice the LDL-chol increased. In addition, ciprofibrate increased plasma post heparin lipoprotein lipase activity (1.3-2.1 fold) in all groups but hepatic lipase activity decreased in treated CETP and non-Tg mice. Plasma CETP activity and liver CETP mRNA levels were significantly increased in treated CIII/CETP and CETP mice (30-100%). Kinetic studies with ³H-cholesteryl ether (CEt) labelled HDL showed a 50% reduction in the ³H-CEt found in the LDL fraction in ciprofibrate treated compared to non-treated CETP mice. This means that ³H-CEt transferred from HDL to LDL was more efficiently removed from the plasma in the fibrate treated mice. Accordingly, the amount of ³H-CEt recovered in the liver 6 hours after HDL injection was increased by 35%.</p> <p>Conclusion</p> <p>Together these data showed that the PPARα agonist ciprofibrate stimulates CETP gene expression and changes the cholesterol flow through the reverse cholesterol transport, increasing plasma cholesterol removal through LDL.</p

Green speciation of iron using aqueous two-phase system

Fe(II) and Fe(III) have distinct chemical and biological functions. Consequently, it is more important to determine the fraction of both oxidation state that knowing the total iron concentration in a sample. However, green methods for iron speciation are still limited. This work uses aqueous two-phase system, a safe alternative to liquid–liquid extraction, to perform the chemical speciation of iron. This method is based on the reaction of Fe(II) with 1,10-phenanthroline extractant, forming a complex of Fe(II)-phenanthroline that concentrates in the top phase of the system. The Fe(III) specie concentrated in the bottom phase of the system. Iron speciation was affected by the electrolyte nature, macromolecule type, quantity of phenanthroline added, and pH. The system formed by PEO1500 + Na3 C6 H5 O7 + H2 O at pH 6.00, containing 5.00 mmol kg–1 of phenanthroline, was successfully used to separate the iron species before determination by flame atomic absorption spectrometry. Under these optimal conditions, a separation factor of 233 was obtained between Fe(II) and Fe(III) with extraction percentages of (95.1 ± 1.0)% and (7.68 ± 0.50)%, respectively The proposed method was successfully applied for iron speciation in water samples, and provided recovery percentages ranging between 90 and 106%

Drug-Eluting Stents in Primary Angioplasty Long-Term Clinical Outcomes

INTRODUCTION: The use of drug-eluting stents in the context of mechanical reperfusion following ST-segment elevation myocardial infarction (MI) was initially viewed with concern. The main fear was that the drugs' action in unstable lesions could increase the risk of thrombotic stent occlusion. Furthermore, there was no evidence that the proven benefit of reduced instent restenosis could be extended to such patients, since they were excluded from the initial clinical trials. OBJECTIVES: To assess the safety and long-term clinical outcomes of the use of drug-eluting stents in primary angioplasty. METHODS: The first 100 consecutive and non-selected patients admitted for MI and treated by primary angioplasty with drug-eluting stent implantation in the target lesion were analyzed retrospectively. The efficacy and safety of the procedure, in-hospital clinical evolution and the occurrence of major adverse cardiac events in the first year were assessed. RESULTS: Patients' mean age was 58.2 +/- 11.5 years, and 78 were male. The success rate of primary angioplasty was 99%. Stents coated with sirolimus were used in 67 patients, paclitaxel in 19 and dexamethasone in 16. In-hospital mortality was 3%. The follow-up rate at 12 months was 98%. During this period, the rate of target vessel revascularization was 1% (with no patient requiring target lesion revascularization), MI 2%, and overall mortality 3.9%. Fourteen patients had clinical indication for repeat coronary angiography, which showed no significant in-stent restenosis. One event was considered to be due to acute stent thrombosis. The incidence of major adverse events was 5.9%. CONCLUSION: The use of drug-eluting stents in MI patients undergoing primary mechanical revascularization is safe and is associated with a reduced incidence of major adverse events, thrombosis and clinical restenosis at one year

Global phylogeography and evolution of chelonid fibropapilloma-associated herpesvirus

A global phylogeny for chelonid fibropapilloma-associated herpesvirus (CFPHV), the most likely aetiological agent of fibropapillomatosis (FP) in sea turtles, was inferred, using dated sequences, through Bayesian Markov chain Monte Carlo analysis and used to estimate the virus evolutionary rate independent of the evolution of the host, and to resolve the phylogenetic positions of new haplotypes from Puerto Rico and the Gulf of Guinea. Four phylogeographical groups were identified: eastern Pacific, western Atlantic/eastern Caribbean, mid-west Pacific and Atlantic. The latter comprises the Gulf of Guinea and Puerto Rico, suggesting recent virus gene flow between these two regions. One virus haplotype from Florida remained elusive, representing either an independent lineage sharing a common ancestor with all other identified virus variants or an Atlantic representative of the lineage giving rise to the eastern Pacific group. The virus evolutionary rate ranged from 1.62x10(-4) to 2.22x10(-4) substitutions per site per year, which is much faster than what is expected for a herpesvirus. The mean time for the most recent common ancestor of the modern virus variants was estimated at 192.90-429.71 years ago, which, although more recent than previous estimates, still supports an interpretation that the global FP pandemic is not the result of a recent acquisition of a virulence mutation(s). The phylogeographical pattern obtained seems partially to reflect sea turtle movements, whereas altered environments appear to be implicated in current FP outbreaks and in the modern evolutionary history of CFPHV.DNER-PR; US NMFS (NMFS-NOAA) [NA08NMF4720436]; US-Fish and Wildlife Service (USFWS); Sociedad Chelonia; WIDECAST; US Environmental Protection Agency (US-EPA); Lisbon Oceanarium, Portugal; Interdisciplinary Research Center for Animal Health of the Faculty of Veterinary Medicine of the Technical University of Lisbon (FMV/TUL)info:eu-repo/semantics/publishedVersio